Skip to content
HowShorted

Oric Pharmaceuticals, Inc. short interest in 2021

In 2021, Oric Pharmaceuticals, Inc.'s disclosed short interest ran from 9.23% of shares outstanding on 15 Jan 2021 to 6.74% on 31 Dec 2021, a change of -2.49 percentage points. The year's high was 17.15% on 15 Apr 2021 and its low 6.74% on 31 Dec 2021, averaging 10.67% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 49.93 days on 28 May 2021. Full history: Oric Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Oric Pharmaceuticals, Inc. in 2021

2021 in figures

Start of year
9.23% (15 Jan 2021)
End of year
6.74% (31 Dec 2021)
Change
-2.49 pp
High
17.15% (15 Apr 2021)
Low
6.74% (31 Dec 2021)
Average
10.67%
Highest days to cover
49.93 (28 May 2021)
SEC filings marked
9

Every report in 2021

Oric Pharmaceuticals, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 20219.23%10.27results (8-K)
29 Jan 202111.23%9.04
12 Feb 202111.09%23.02
26 Feb 202111.23%24.92
15 Mar 202111.71%20.29
31 Mar 202115.41%12.8510-K filed, results (8-K)
15 Apr 202117.15%25.01
30 Apr 202114.96%32.10
14 May 202115.20%40.6010-Q filed, results (8-K)
28 May 202114.96%49.93
15 Jun 202115.42%25.05
30 Jun 202115.02%14.19
15 Jul 20218.58%12.72
30 Jul 20219.15%24.61
13 Aug 20218.52%20.6110-Q filed, results (8-K)
31 Aug 20218.21%20.75
15 Sep 20217.81%21.35
30 Sep 20217.65%9.62
15 Oct 20217.50%4.22
29 Oct 20217.40%17.13
15 Nov 20217.42%18.3810-Q filed, results (8-K)
30 Nov 20217.16%22.48
15 Dec 20217.27%14.36
31 Dec 20216.74%14.40

See also: Oric Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.